Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8264963 | 0.98 | CYP2C19 (0.50) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL1186304 | 0.94 | CYP2C19 (0.46) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL380983 | 0.90 | GAA (0.48) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL23896804 | 0.83 | KMT2A (0.44) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL28630400 | 0.82 | GAA (0.44) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL4577419 | 0.82 | GAA (0.44) | GAAMGAMSIMGAM2KDM4E | |
| SCHEMBL16169964 | 0.81 | CTDSP1 (0.38) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL4113341 | 0.81 | OPRM1 (0.43) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL2085077 | 0.81 | TSHR (0.44) | CYP2C19GAAMGAMSIMGAM2 | |
| SCHEMBL25025741 | 0.81 | ALDH1A1 (0.42) | CYP2C19GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-110183449-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2021-11-04 | — | — | US | disclosed |
| CN-111218158-A | Ink formula for ink-jet printing | 福建奥博兹新材料科技有限公司 | 2020-06-02 | — | — | CN | disclosed |
| CN-110183449-A | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2019-08-30 | — | — | CN | disclosed |
| EP-3521289-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | Effector Therapeutics Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-106795162-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (NL) | 2018-03-29 | — | — | US | disclosed |
| EP-1740584-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105802-A1 | FUSED QUINOLINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-6159964-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0412110-B1 | NOVEL VITAMIN D ANALOGUES | LEO PHARM PROD LTD (DK) | 1993-07-07 | — | — | EP | disclosed |
| US-5206229-A | Inhibit cell proliferation, antiinflammatory, treating imbalance of immune system | LEO PHARMACEUTICAL PRODUCTS LTD (DK) | 1993-04-27 | — | — | US | disclosed |
| EP-0412110-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1991-02-13 | — | — | EP | disclosed |
| WO-1989010351-A1 | NOVEL VITAMIN D ANALOGUES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1989-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209560-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP2C19 3973/4885GAA 1292/4885MGAM 873/4885 |
| US-20180085368-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP2C19 3973/4885GAA 1292/4885MGAM 873/4885 |
| US-20210338673-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | TNNI3K, NIM1K, NEK9 | CYP2C19 3973/4885GAA 1292/4885MGAM 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.